Healthy Skepticism Library item: 5543

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: Journal Article

Breggin PR
Court filing makes public my previously suppressed analysis of Paxil's effects.
Ethical Human Psychology and Psychiatry 2006 Spr; 8:(1):77-84
http://www.springerpub.com/

Abstract:

In this article, the author describes his participation as a medical expert in a product liability case brought by the family of Reynaldo Lacuzong against the drug company Glaxo SmithKline (GSK) in California. In 2005, his report in the Lacuzong case was filed as a part of a motion in another Paxil case, Moffett v. Glaxo SmithKline, in the United States District Court for the Southern District of Mississippi. Because it was filed in the public record, his report is now available to the public, and he is able to comment on the details. The following excerpts include Sections XI-XIV of the report that can be found in its entirety on www.breggin.com. These excerpted sections focus on Paxil-induced suicidality in adults—the subject of a current FDA investigation. Other sections deal with numerous issues including FDA correspondence criticizing the company, advertising and promotion, the drug label, rates of adverse psychiatric effects after only a few doses, akathisia, and the stimulant or activation continuum. A lengthy, detailed summary and conclusion can be found in the complete report.

Keywords:
Paxil, suicidality, FDA, advertising, promotion, adverse events, legal case